Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell
lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

Immune checkpoint inhibition as a new treatment approach is undergoing extensive
investigation in non–small cell lung cancer (NSCLC) and other malignancies. Unlike …

Abstract Immune-checkpoint inhibitors (ICI), particularly inhibitors of the PD-1 axis, have
altered the management of non–small cell lung cancer (NSCLC) over the last 10 years. First …

Lung cancer is one of the most common cancers and the leading cause of cancer-related
deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present …

Lung cancer is the most common cancer and leading cause of cancer death. While targeted
therapies have redefined treatment options for non-small cell lung carcinoma (NSCLC) with …

Many decades in the making, immunotherapy has demonstrated its ability to produce
durable responses in several cancer types. In the last decade, immunotherapy has shown …

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has become a “game
changer” in the treatment of advanced non-small cell lung cancer (NSCLC). Its most …